ISSN 2149-2247 | E-ISSN 2149-2549
Invited Review
Navigating through Mutations in Acute Myeloid Leukemia. What Do We Know and What Do We Do with It?
1 The University of Alabama at Birmingham, Comprehensive Cancer Center, US  
Erciyes Med J ; : -
DOI: 10.5152/etd.2018.0136
Key Words: AML, mutations, cytogenetics, targeted therapies
Abstract

Acute myeloid leukemia (AML) is a clonal hematopoietic disease characterized by abnormal proliferation of early precursors of myeloid cells and blasts. AML represents a heterogeneous disease group with a significantly complex biology and pathophysiology. Various translocations, chromosome copy number changes and mutations have been described in AML, some of which help define the diagnosis, prognosis and management. The optimal treatment in most cases remains cytarabine and anthracycline-based combination regimens followed by the allogeneic stem cell transplant. However, older age and decreased tolerance to conventional therapies pose a major challenge for the conventional therapies which has lead to the development of effective and less toxic therapy modalities as reviewed in this manuscript.


Cite this article as
: Peker D. Navigating through Mutations in Acute Myeloid Leukemia. What Do We Know and What Do We Do with It? Erciyes Med J 2018; DOI: 10.5152/etd.2018.0136

Key Words
Authors
All
Author’s Corner
Survey
AVES | Copyright © 2018 Erciyes University Faculty of Medicine | Latest Update: 03.10.2018